COPENHAGEN, Denmark, March 12, 2018 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, announces it has entered into a collaborative agreement with Merck & Co.,...